Tubulis is developing unique antibody-drug conjugates (ADC’s) for a range of solid tumour indications. To this end, the company utilises its own technology platform which enables ADC’s to be generated flexibly and in line with the requirements of the individual indication. This increases the therapeutic potential of the ADC’s and addresses the central limitations of existing ADC technologies in terms of toxicity, efficacy and limited indication selection. In combination with sound biological know-how and new mechanisms of action, Tubulis is generating a pipeline of versatile ADC candidates that have the potential to expand the current range of applications of ADC’s and enable more targeted drug delivery. The company’s goal is to use this innovative approach to unlock the full therapeutic potential of ADCs in order to improve treatment outcomes for a large number of cancer patients.
"Tubulis impressively demonstrates what healthcare science made in Bavaria can look like. We at Bayern Kapital are proud to support companies that can significantly improve treatments for patients.”
Franz Wocheslander, Senior Investment Manager at Bayern Kapital